Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001662774-25-000012
Filing Date
2025-03-24
Accepted
2025-03-24 16:07:24
Documents
125
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K qncx-20241231.htm   iXBRL 10-K 2339912
2 EX-4.3 exhibit43-descriptionofsec.htm EX-4.3 23202
3 EX-10.15 exhibit1015-quincexoutside.htm EX-10.15 38123
4 EX-19.1 ex-191xquincexinsidertradi.htm EX-19.1 88921
5 EX-21.1 ex211-listofsubsidiaries.htm EX-21.1 5949
6 EX-23.1 ex-231xex231consentofindep.htm EX-23.1 2576
7 EX-31.1 qncx-20241231xexx311.htm EX-31.1 10019
8 EX-31.2 qncx-20241231xexx312.htm EX-31.2 10254
9 EX-32.1 qncx-20241231xexx321.htm EX-32.1 6819
10 EX-32.2 qncx-20241231xexx322.htm EX-32.2 6858
16 qncx-20241231_g1.jpg GRAPHIC 79475
17 qncx-20241231_g2.jpg GRAPHIC 214646
18 qncx-20241231_g3.jpg GRAPHIC 84736
19 qncx-20241231_g4.jpg GRAPHIC 77927
20 qncx-20241231_g5.jpg GRAPHIC 133830
21 qncx-20241231_g6.jpg GRAPHIC 55651
  Complete submission text file 0001662774-25-000012.txt   13476720

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20241231.xsd EX-101.SCH 81628
12 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT qncx-20241231_cal.xml EX-101.CAL 124319
13 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT qncx-20241231_def.xml EX-101.DEF 443985
14 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20241231_lab.xml EX-101.LAB 930331
15 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20241231_pre.xml EX-101.PRE 725780
127 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20241231_htm.xml XML 1562308
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38890 | Film No.: 25764226
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)